Novo Holdings has recently completed a $16.5 billion buyout of biotechnology company, Catalent (CTLT), despite stumbling blocks such as scrutiny from US Senator Warren and several consumer groups. The transaction received unconditional approval from the European Commission, causing Catalent's stock to rise 3.2% since its last earnings report. However, other reports suggest that Catalent has been running into some headwinds. The company missed Q1 revenue estimates and reported a potential hindrance to the NVO buyout deal. Catalent also experienced control lapses at a plant being sold to Novo, causing its stock to fall. Amid these issues, Catalent continues to make strategic moves. It recently signed an agreement to sell its Somerset, NJ Oral Solids Facility and issued an open letter to its customers. Looking forward, it'll be important to watch out for the company's next quarterly earnings report. Its Q4'24 earnings surpassed expectations, with an EPS of $0.13 and revenue at $1.30 billion. However, it should be noted that some Catalent investors incurred a loss of 47% if they invested three years ago.
Catalent CTLT News Analytics from Wed, 19 Aug 2020 10:01:55 GMT to Sat, 04 Jan 2025 07:15:46 GMT -
Rating 3
- Innovation -3
- Information 7
- Rumor -7
